Phase I Clinical Study of Combination Therapy with Eribulin and Gemcitabine in Patients with Progressive Recurring Breast Cancer (JBCRG-18Gem)

Trial Profile

Phase I Clinical Study of Combination Therapy with Eribulin and Gemcitabine in Patients with Progressive Recurring Breast Cancer (JBCRG-18Gem)

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2015

At a glance

  • Drugs Eribulin (Primary) ; Gemcitabine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms JBCRG-18Gem
  • Most Recent Events

    • 22 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by University Hospital Medical Information Network - Japan.
    • 25 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 31 Dec 2013 Planned End Date changed from 30 Nov 2013 to 30 Nov 2014 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top